About Us

As a service provider Alcyomics aspires to take the lead in providing unique screening services enabling more cost-effective commercialisation of products and or drugs offering a reliable alternative to animal testing for safety and potency assessment of novel compounds. We use our patented technology, Skimune®, a non-artificial human skin explant test to accurately predict adverse immune reactions. For example we can assist in clinical trial development by evaluation of dose response. We work to Good Laboratory Practice and to ISO9001 standards and our safety and efficacy reports have been submitted to regulatory authorities to support, for example clinical trial applications.

Skimune® represents the fruits of over 30 years’ research on haematopoietic stem cell transplantation and Graft versus Host Disease (GvHD) by Alcyomics CEO, Anne Dickinson Emeritia Professor of Translational and Clinical Medicine at Newcastle University, who used human skin based in vitro assays for identifying responses of donor cells against patient skin tissue i.e. graft versus host disease (GvHD) following haematopoietic stem cell transplantation. Her research work that has been extensively published in over 100 peer-reviewed journals. This skin explant predictive assay for GvHD has been used in Newcastle as part of a clinical protocol for treatment of haematological disorders and has been published to have a >80% correlation with clinical outcome. Since GvHD affects more than one target organ e.g. skin, gut and liver, the assay is predictive of systemic disease.